Literature DB >> 17097110

Genetic analysis of LRRK2 mutations in patients with Parkinson disease.

Hao Deng1, WeiDong Le, Yi Guo, Christine B Hunter, WenJie Xie, MaoSheng Huang, Joseph Jankovic.   

Abstract

In addition to the G2019S mutation in the leucine-rich repeat kinase 2 gene (LRRK2), which is particularly frequent in patients of Ashkenazi Jewish and Northern African origin, three amino acid substitutions (R1441C, R1441G, and R1441H), all at the same residue (R1441), have been identified as important genetic causes of Parkinson disease (PD). To evaluate the frequency of R1441C/G/H and G2019S mutations in the LRRK2 gene in North American patients with PD and to explore genotype-phenotype correlations, we screened 496 PD patients from North America. One Hispanic female was heterozygous for the LRRK2 R1441G mutation, and six other cases including 2 non-Jewish/non-Hispanic whites, 3 Ashkenazi Jewish, and 1 Hispanic, were found to be heterozygous for the LRRK2 G2019S mutation. G2019S mutation in the LRRK2 gene is a common mutation associated with PD in a North American population, especially in Jewish PD patients (10.7%), while the R1441C/G/H mutation occurs at a relatively low frequency in North Americans except possibly in Hispanics for R1441G. All six G2019S carriers shared a common haplotype with that observed in Europeans and North Africans. The clinical features of all seven cases with LRRK2 mutation were quite broad and included early and late disease onset. These finding may provide new insights into the cause and diagnosis of PD and have implications for genetic counseling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097110     DOI: 10.1016/j.jns.2006.09.017

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  18 in total

Review 1.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

2.  LRRK2 G2019S mutations may be increased in Puerto Ricans.

Authors:  Rachel Saunders-Pullman; Jose Cabassa; Marta San Luciano; Kaili Stanley; Deborah Raymond; Laurie J Ozelius; Susan B Bressman
Journal:  Mov Disord       Date:  2011-03-29       Impact factor: 10.338

Review 3.  LRRK2 links genetic and sporadic Parkinson's disease.

Authors:  Jillian H Kluss; Adamantios Mamais; Mark R Cookson
Journal:  Biochem Soc Trans       Date:  2019-03-05       Impact factor: 5.407

4.  Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.

Authors:  R Djaldetti; S Hassin-Baer; M J Farrer; C Vilariño-Güell; O A Ross; V Kolianov; S Yust-Katz; T A Treves; Y Barhum; M Hulihan; E Melamed
Journal:  J Neural Transm (Vienna)       Date:  2008-07-30       Impact factor: 3.575

Review 5.  The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers.

Authors:  Rivka Inzelberg; Simon D Israeli-Korn
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 6.  Genes associated with Parkinson's disease: regulation of autophagy and beyond.

Authors:  Alexandra Beilina; Mark R Cookson
Journal:  J Neurochem       Date:  2015-09-03       Impact factor: 5.372

7.  Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.

Authors:  Taku Hatano; Manabu Funayama; Shin-Ichiro Kubo; Ignacio F Mata; Yutaka Oji; Akio Mori; Cyrus P Zabetian; Sarah M Waldherr; Hiroyo Yoshino; Genko Oyama; Yasushi Shimo; Ken-Ichi Fujimoto; Hirokazu Oshima; Yasuto Kunii; Hirooki Yabe; Yoshikuni Mizuno; Nobutaka Hattori
Journal:  Neurobiol Aging       Date:  2014-06-02       Impact factor: 4.673

8.  Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain.

Authors:  Ignacio F Mata; Carolyn M Hutter; María C González-Fernández; Marian M de Pancorbo; Elena Lezcano; Cecilia Huerta; Marta Blazquez; Renee Ribacoba; Luis M Guisasola; Carlos Salvador; Juan C Gómez-Esteban; Juan J Zarranz; Jon Infante; Joseph Jankovic; Hao Deng; Karen L Edwards; Victoria Alvarez; Cyrus P Zabetian
Journal:  Neurogenetics       Date:  2009-03-24       Impact factor: 2.660

9.  Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.

Authors:  Joana Meireles; João Massano
Journal:  Front Neurol       Date:  2012-05-25       Impact factor: 4.003

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.